CY1120471T1 - Αντισωματα κατα του cd70 - Google Patents

Αντισωματα κατα του cd70

Info

Publication number
CY1120471T1
CY1120471T1 CY20181100783T CY181100783T CY1120471T1 CY 1120471 T1 CY1120471 T1 CY 1120471T1 CY 20181100783 T CY20181100783 T CY 20181100783T CY 181100783 T CY181100783 T CY 181100783T CY 1120471 T1 CY1120471 T1 CY 1120471T1
Authority
CY
Cyprus
Prior art keywords
antibodies
bind
antigens
fragments
protein
Prior art date
Application number
CY20181100783T
Other languages
English (en)
Inventor
Karen Silence
Peter Ulrichts
Johannes Joseph Wilhelmus De Haard
Torsten Dreier
Michael John Scott Saunders
Harald Wajant
Sofie Maria Elvire GABRIELS
Mahan Moshir
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of CY1120471T1 publication Critical patent/CY1120471T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Η παρούσα εφεύρεση αφορά σε αντισώματα και θραύσματα που προσδένουν αντιγόνα αυτών, τα οποία δεσμεύονται στην ανθρώπινη πρωτεΐνη CD70 με υψηλή συγγένεια και επιδεικνύουν ισχυρή αναστολή της ανάπτυξης ογκοκυττάρων.
CY20181100783T 2011-03-16 2018-07-27 Αντισωματα κατα του cd70 CY1120471T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453390P 2011-03-16 2011-03-16
US201161503871P 2011-07-01 2011-07-01
PCT/EP2012/054733 WO2012123586A1 (en) 2011-03-16 2012-03-16 Antibodies to cd70

Publications (1)

Publication Number Publication Date
CY1120471T1 true CY1120471T1 (el) 2019-07-10

Family

ID=45878935

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100783T CY1120471T1 (el) 2011-03-16 2018-07-27 Αντισωματα κατα του cd70

Country Status (18)

Country Link
US (6) US9765148B2 (el)
EP (1) EP2686347B1 (el)
JP (2) JP5982409B2 (el)
CN (1) CN103596979B (el)
AU (1) AU2012228194B2 (el)
BR (1) BR112013021562B1 (el)
CA (1) CA2828753C (el)
CY (1) CY1120471T1 (el)
DK (1) DK2686347T3 (el)
ES (1) ES2670874T3 (el)
HU (1) HUE039849T2 (el)
IL (1) IL228001B (el)
PL (1) PL2686347T3 (el)
PT (1) PT2686347T (el)
RU (1) RU2604196C2 (el)
SI (1) SI2686347T1 (el)
TR (1) TR201807202T4 (el)
WO (1) WO2012123586A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
RS58528B1 (sr) * 2012-12-03 2019-04-30 Bristol Myers Squibb Co Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina
CA2910553A1 (en) * 2013-04-30 2014-11-06 Universite De Montreal Novel biomarkers for acute myeloid leukemia
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019149743A1 (en) 2018-01-30 2019-08-08 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
JP7404247B2 (ja) 2018-02-01 2023-12-25 ファイザー・インク Ｃｄ７０を標的とするキメラ抗原受容体
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US20220047634A1 (en) * 2018-11-30 2022-02-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
EP4173638A1 (en) * 2020-06-30 2023-05-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd70 antibody and application thereof
US20230266332A1 (en) 2020-07-28 2023-08-24 Inserm (Institut National De La Santè Et De La Recherch Médicale) Methods and compositions for preventing and treating a cancer
IL302728A (en) 2020-11-13 2023-07-01 Catamaran Bio Inc Genetically modified natural killer cells and methods of using them
EP4257617A1 (en) 2020-12-01 2023-10-11 Cure Genetics Co., Ltd Antigen-binding protein targeting cd70 and use thereof
CN114685657A (zh) * 2020-12-31 2022-07-01 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN116375865A (zh) * 2021-06-17 2023-07-04 南京蓝盾生物科技有限公司 具有增强的adcp效应的抗cd70抗体及其应用
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
WO2003039443A2 (en) 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
US7728114B2 (en) * 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2005295595C1 (en) * 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006047249A1 (en) 2004-10-22 2006-05-04 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP1872124A4 (en) 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
US8455622B2 (en) * 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
EP2217223A2 (en) 2007-11-05 2010-08-18 Novartis AG Methods and compositions for measuring wnt activation and for treating wnt-related cancers
DK2276509T3 (en) * 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CA2725919A1 (en) 2008-05-28 2009-12-03 Roland Antonius Paulus Romijn Method for the production of proteins or protein fragments
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2010070145A2 (en) * 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
DK2987487T3 (da) 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EA021356B1 (ru) 2009-11-19 2015-05-29 Мерк Сероно С.А. Гуманизированные антитела против il-22ra человека
EP2520589B1 (en) 2009-12-29 2018-11-07 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
TR201807750T4 (tr) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
EP2665749B1 (en) 2011-01-19 2016-01-13 Cantargia AB Anti-il1rap antibodies and their use for treating solid tumours
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
BR122020002414B1 (pt) 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
CN104394884A (zh) 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
EP2861590B1 (en) 2012-06-15 2017-10-25 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
RS56169B1 (sr) 2013-02-14 2017-11-30 Bristol Myers Squibb Co Jedinjenja tubulisina, metode pripreme i primena
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3125645A1 (en) 2015-07-31 2017-02-01 Bleckmann GmbH & Co. KG Flange assembly for securing a heating device to a fluid container
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017044752A1 (en) 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy

Also Published As

Publication number Publication date
TR201807202T4 (tr) 2018-06-21
JP2016196471A (ja) 2016-11-24
SI2686347T1 (en) 2018-08-31
AU2012228194B2 (en) 2017-06-01
US20190270823A1 (en) 2019-09-05
HUE039849T2 (hu) 2019-02-28
AU2012228194A1 (en) 2013-09-12
WO2012123586A1 (en) 2012-09-20
EP2686347A1 (en) 2014-01-22
EP2686347B1 (en) 2018-05-02
US9765149B2 (en) 2017-09-19
ES2670874T3 (es) 2018-06-01
JP2014509861A (ja) 2014-04-24
DK2686347T3 (en) 2018-06-25
US20150266963A1 (en) 2015-09-24
CA2828753A1 (en) 2012-09-20
JP6261651B2 (ja) 2018-01-17
US8834882B2 (en) 2014-09-16
US20140147450A1 (en) 2014-05-29
IL228001A0 (en) 2013-09-30
CA2828753C (en) 2022-07-26
US11434298B2 (en) 2022-09-06
PL2686347T3 (pl) 2018-10-31
BR112013021562B1 (pt) 2023-01-10
CN103596979A (zh) 2014-02-19
IL228001B (en) 2018-06-28
BR112013021562A2 (pt) 2016-11-08
JP5982409B2 (ja) 2016-09-07
US20140235843A1 (en) 2014-08-21
US11072665B2 (en) 2021-07-27
US20230265201A1 (en) 2023-08-24
US9765148B2 (en) 2017-09-19
PT2686347T (pt) 2018-07-05
RU2604196C2 (ru) 2016-12-10
CN103596979B (zh) 2018-01-26
US20140141016A1 (en) 2014-05-22
RU2013146106A (ru) 2015-04-27
US20170369581A9 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1123435T1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
TN2015000396A1 (en) Antibody drug conjugates
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201291065A1 (ru) Антитела против vla-4
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения